HALIX B.V. signed an agreement with AstraZeneca AB for large-scale commercial drug substance manufacture of AZD1222, the adenovirus vector-based COVID-19 vaccine.<\/p>\n\n\n\n
Under the agreement, HALIX will provide commercial manufacturing of drug substance at its state-of-the-art cGMP facility at the Leiden Bio Science Park in the Netherlands. To meet the increased demand, HALIX expands with two additional viral vector production lines.<\/p>\n\n\n\n
With this agreement, HALIX continues its key role as one of the original partners in the University of Oxford\u2019s consortium for the manufacture of AZD1222. The vaccine was co-invented by the University of Oxford and its spin-out company Vaccitech.<\/p>\n\n\n\n